Sickle Cell Disease Trial, Recruiting NCT06691867 Sponsor: Emory University Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Sickle Cell Disease Trial, Recruiting

NCT06691867
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The adolescent (and their caregiver, if applicable) must sign and date a consent form agreeing to take part
  • For young people under 18, both the young person's agreement and a parent or guardian's signed permission are required
  • Participants must be willing to follow all study steps and be available for the full length of the study
  • The adolescent must be between 12 and 18 years old; caregivers of any age may also participate
  • The adolescent must have a confirmed diagnosis of sickle cell disease (any type)
  • The adolescent must score at least 3 on a standard pain screening tool used for young people (confirm with trial site)
  • The adolescent must rate their typical pain over the past week as at least 4 out of 10 on a pain scale
  • If the adolescent is taking any sickle cell medications (such as hydroxyurea or similar treatments), the dose must have been stable for at least the past 3 months
  • Both the adolescent and caregiver must be able to speak and read English

Who may not be able to join:

  • The adolescent has another medical condition not related to sickle cell disease that also causes pain (such as certain joint or bowel conditions)
  • The adolescent has previously had gene therapy or a stem cell transplant
  • The adolescent has any physical or mental health condition that would prevent safe participation in the study (confirm with trial site)
  • The adolescent is currently receiving regular non-medication pain treatment (such as structured therapy sessions, physical therapy, or acupuncture) that would overlap with this study's active period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Soumitri Sil, PhD, ABPP, Emory University

Phone: 404-727-2712

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 January 2025
Est. completion
1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Brief Pain Inventory (BPI) Pain severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov